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We present a case of drug reaction with eosino-
philia and systemic symptoms (DRESS) syndrome
associated with griseofulvin, which, to our knowl-
edge, has not been previously reported.CASE REPORT
A 69-year-old woman otherwise well, with no
known allergies and not on any regular medications,
was prescribed 500 mg griseofulvin daily to treat
tinea interdigitale. Six days later she noticed red
papules appearing on her torso. Over the next
4 days, her eruption progressed to involve her limbs,
and she became febrile, lost her appetite, and felt
generally unwell. Griseofulvin was ceased, and she
presented to the emergency department of a tertiary
hospital and was admitted under a medical team. On
admission, she was found to be febrile (37.98C) and
lymphopenic with mild nephritic syndrome and
facial swelling. During her admission, the patient
had an eosinophilia (1.06 3 109/L), palpable lymph
nodes in the cervical and inguinal regions, and
extension of her eruption, which was predominantly
a macular erythema over her trunk and proximal
limbs (Fig 1). There was no mucosal involvement.
According to the Bocquet et al and RegiSCAR criteria,
this patient met a diagnosis of DRESS. Skin biopsy
found interface change, superficial and perivascular
chronic inflammatory cell infiltrate, and moderate
numbers of interstitial eosinophils, consistent with a
drug eruption (Fig 2). The patient was observed over
the next few days until her renal function and
hematologic derangement normalized. On reviewthe Departments of Dermatologya and Anatomical Pathol-
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episodes.DISCUSSION
DRESS is a rare but serious adverse drug reaction
presenting with variable signs of both cutaneous and
internal organ involvement.1-3 Generally, symptoms
develop 2 to 8 weeks after initiation of the causative
medication.4,5 Drugs most commonly implicated
include antiepileptics, allopurinol, sulphonamides,
minocycline, and nonsteroidal anti-inflammatory
drugs. Our patient had a reaction faster than usual
for DRESS. Despite this fast reaction, enough criteria
were met to diagnose DRESS with both Bocquet et al
and RegiSCAR criteria.1-3,6
Griseofulvin has not been previously reported to
be associated with DRESS. It is known to cause
phototoxic and photoallergic eruptions. Themedical
literature is studded with case reports of other forms
of drug hypersensitivity secondary to griseofulvin,
including serum sicknesselike reaction,7 acute
generalized exanthematous pustulosis,8 fixed drug
eruption,9 subacute cutaneous lupus erythemato-
sus,10 and toxic epidermal necrolysis.11
The United Kingdom Medicines and Healthcare
products Regulatory Agency lists griseofulvin as
being reported to cause a variety of hypersensitivityJAAD Case Reports 2016;2:315-6.
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Fig 1. A, Diffuse macular erythema almost confluent over
the torso. B, Closer view of erythema on torso.
Fig 2. A, Widespread basal vacuolar change (arrows) with
focal basal lymphocyte exocytosis, involving an epidermis
of normal thickness, with retained basket weave pattern of
keratin. B, Dermal edema and a moderately heavy super-
ficial perivascular lymphohistiocytic infiltrate with moder-
ate numbers of interstitial eosinophils (arrows).
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bullous disorders (particularly erythema multi-
forme), urticaria, various exanthems, and exfoliative
dermatitis. DRESS is not listed.12 The AustralianTherapeutic Goods Administration Database of
Adverse Events Notifications has a similar listing
and also does not report DRESS with griseofulvin.13
The United States Food and Drug Administration
emphasizes the risk of erythema multiforme,
Stevens-Johnson syndrome, and toxic epidermal
necrolysis but does not list DRESS under the Severe
Skin Reactions warning for griseofulvin.14
Clinically, our patient’s cutaneous eruption and
systemic features were most in keeping with a
diagnosis of DRESS, despite the short timeline. This
case reminds the clinician to consider a diagnosis of
DRESS for any drug, even in the absence of a classic
drug cause.REFERENCES
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